SPRB Stock Forecast & Price Target

Spruce Biosciences is viewed positively because TA-ERT appears to be the leading therapy in a high-unmet-need MPS IIIB market, with FDA commentary at the 9/23 conference reinforcing regulatory flexibility and supporting a 4Q26 BLA submission based on biomarker and long-term clinical data. The investment case is strengthened by an estimated ~$60M enterprise value versus a ~75% probability of approval, a possible Priority Review Voucher worth ~$150M+, and modeled commercial opportunity of about $170M, while peak sales are estimated above $300M by physician checks. With $96M in cash, runway into 2H27, and an expanding patient-access and confirmatory-study plan for 4Q26, the company appears financially and clinically positioned for a de-risked path to approval.

Spruce Biosciences is burdened by a fragile financial profile, with 2Q26 operating expenses of $17M exceeding consensus and a net loss of $16M, or ($6.68)/share, underscoring that losses remain wide relative to expectations. Its outlook is further constrained by a limited pipeline, with TA-ERT still the lead asset and SPR202 only in preclinical development, leaving the company highly dependent on a single program. Even with Phase 2 data for TA-ERT, regulatory, commercial, and financing risks remain elevated because MPS IIIB has no approved therapies, market economics are unclear, and additional capital raises could dilute shareholders.